BofA lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $32 from $34 and keeps a Buy rating on the shares. While telling investors that Rocket’s incremental Q1 update was “likely overshadowed” by its late-breaker oral at ASGCT, the firm was “nonetheless encouraged by the progress” and continues to like the second half setup. The firm continues to see opportunities for a re-rating as Rocket moves towards commercialization, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals announces serious adverse event in RP-A501 trial
- Promising Phase 1 Results for Rocket Pharmaceuticals’ RP-A601 Highlight Investment Potential
- Rocket Pharmaceuticals price target raised to $30 from $20 at Cantor Fitzgerald
- Promising Phase I Data and Strategic Focus Drive Buy Rating for Rocket Pharmaceuticals
- Rocket Pharmaceuticals price target raised to $46 from $45 at Chardan